



18 July 2017

**Motif Bio plc**  
**("Motif" or the "Company")**

**Amendment to Amphion Innovations Consultancy Agreement**

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that it has amended the terms of its consultancy agreement with Amphion Innovations plc.

On April 1, 2015, the Group entered into a consultancy agreement with Amphion Innovations plc for the services of Robert Bertoldi, an employee of Amphion Innovations plc. The consideration for his services was US \$5,000 per month. On November 1, 2015, the consideration was increased to US \$180,000 per annum. On July 1, 2016, the consideration decreased to US \$75,000. Motif has now increased the consideration to US \$125,000 to better reflect Robert Bertoldi's time commitment to Motif.

The amendment to the consultancy agreement constitutes a related party transaction under AIM Rule 13 of the AIM Rules for Companies as Amphion Innovations plc is a substantial shareholder of Motif. With the exception of Robert Bertoldi and Richard Morgan, the directors of the Company, having consulted with the Company's nominated adviser, Peel Hunt LLP, consider that the increase in consideration under the consultancy agreement is fair and reasonable insofar as its shareholders are concerned.

For further information please contact:

**Motif Bio plc**

Graham Lumsden (Chief Executive Officer)  
Robert Dickey IV (Chief Financial Officer)

info@motifbio.com

**Peel Hunt LLP (NOMAD & BROKER)**

Dr Christopher Golden  
Oliver Jackson

+ 44 (0)20 7418 8900

**Northland Capital Partners Limited (BROKER)**

Patrick Claridge/ David Hignell  
John Howes/ Rob Rees (Broking)

+44 (0)203 861 6625

**Walbrook PR Ltd. (FINANCIAL PR & IR)**

Paul McManus  
Mike Wort

+44 (0) 20 7933 8780 or motifbio@walbrookpr.com

Mob: +44 (0)7980 541 893

Mob: +44 (0)7900 608 002

**MC Services AG (EUROPEAN IR)**

Raimund Gabriel

+49 (0)89 210 2280

**Notes to Editors**  
**About Motif Bio**

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin-resistant *Staphylococcus aureus*). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.